Explore the words cloud of the HAPGuide project. It provides you a very rough idea of what is the project "HAPGuide" about.
The following table provides information about the project.
UAB INOVATYVI MEDICINA
|Coordinator Country||Lithuania [LT]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-07-01 to 2019-12-31|
Take a look of project's partnership.
|1||UAB INOVATYVI MEDICINA||LT (VILNIAUS)||coordinator||50˙000.00|
'UAB 'Inovatyvi medicina' has developed an innovative design of endovascular robotic system HAPGuide. This SMART and SENSING technology allows to perform endovascular procedures without medical personnel being exposed to harmful X-rays. HAPGuide solves the main issues of existing robotic systems and opens up possibilities for safer, faster and more effective endovascular interventions in EU and Worldwide. In comparison to existing systems (with only visual feedback and videogame like control) the main HAPGuide advantage is the haptic feedback and traditional control of endovascular instruments using fine-tuned surgeons’ perception-action-visualization abilities. Future developments involve HAPGuide use in telemedicine and partially automated functions via machine learning. Our system is designed to use all standard endovascular instruments and avoids the need of expensive catheters dedicated for the system. The primary target market of HAPGuide is cath labs performing percutaneous coronary interventions and peripheral vascular procedures in EU and US (more than 5.6 mln. procedures annually). The estimated market potential of HAPGuide robotic system in primary worldwide market exceeds €4 billion. The secondary target market would involve neurointerventional procedures while in the long-run expansion to telerobotics will create new market opportunities. Our revenue model involves four main components: 1) durable robotic HAPGuide system; 2) single use cassette; 3) annual service of the system; 4) HAPLearn training software. A multidisciplinary team with vast experience in medical sciences, medical device development, robotics, mechanical and electronic engineering, product design, commercialisation and business development has joined forces for the implementation of HAPGuide project aiming to bring the technology to clinical practice for benefit of patients, physicians and hospitals and exploit this €4 billion niche market commercial opportunity.'
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HAPGUIDE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HAPGUIDE" are provided by the European Opendata Portal: CORDIS opendata.
Carbon Offset Plug-inRead More
COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLESRead More
Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.Read More